Personalis to Participate at the Craig-Hallum 22nd Annual Investor Conference

FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the Craig-Hallum 22nd Annual Investor Conference on Wednesday, May 28, 2025, at The Depot Renaissance Hotel in Minneapolis, MN.

About Personalis, Inc.

At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit www.personalis.com and connect with us on LinkedIn and X (Twitter).

View source version on businesswire.com: https://www.businesswire.com/news/home/20250514343972/en/

Investors:
Caroline Corner
[email protected]
415-202-5678

Media:
[email protected]

Source: Personalis, Inc.

You May Also Be Interested In

• Teledyne Qioptiq Receives First Option from Germany for Additional PHOENIX-XR Cooled Thermal Weapon Sights Valued at More Than $21 Million
• PureTech Health: Notice of Half-Yearly Results
• MentionOS AI Launches an Autonomous AEO Agent That Analyzes What ChatGPT, Gemini, and Other LLMs Say About Brands, Then Helps Get Them Mentioned